Corporate Banner
Satellite Banner
Technology Networks Header
Friday, October 31, 2014
Technology Networks
 
Register | Sign in
Home Page > Posters
  Posters

Automated High Throughput Nucleofection®
Using primary cells for RNAi based applications such as target identification or – validation, requires a highly efficient transfection technology in combination with a reliable and robust automation system. To accomplish these requirements we integrated the amaxa 96-well Shuttle® in a Tecan Freedom EVO® cell transfection workstation which is based on Tecan’s Freedom EVO® liquid handling platform and include all the necessary components and features for unattended cell transfection.

Date Posted: 29/07/2008
ePosters.net Ref: EP


For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here

Scientific News
LLNL, UC Davis Partner to Personalize Cancer Medications
With a $7.8 million, five-year grant from the NIH researchers are utilizing accelerator mass spectrometry for cancer research.
To Wilt or Not to Wilt
UC Riverside researchers identify new process that explains why tomatoes are susceptible to a disease-causing fungus.
A Double-edged Sword
An enzyme key to DNA repair can worsen tissue damage caused by stroke and organ transplantation.
Silencing the FOXP2 Speech Gene Causes Breast Cancer Cells to Metastasize
BIDMC investigators make the surprising discovery that a gene associated with speech and language is linked to advanced breast cancer.
Fast Modeling Of Cancer Mutations
New genome-editing technique enables rapid analysis of genes mutated in tumors.
New Test can Help Doctors Choose Best Treatment for Ovarian Cancer
ADNEX discriminate between benign and malignant tumours with a high level of accuracy.
All the Cell’s a Stage
Brian Strahl, PhD, and his band of biochemists unravel the complicated mysteries of the epigenetic code to find a culprit in cancer development.
New Cancer Drug To Begin Trials In Multiple Myeloma Patients
Scientists at Imperial College London have developed a new cancer drug which they plan to trial in multiple myeloma patients by the end of next year.
ISB Gets $6.5 Million from NCI
Company has received two-year contract to create ‘Cancer Genomics Cloud’ with partners Google and SRA International.
Precise Control Over Genes Results from Game-Changing Research
UCSF invention greatly amplifies power of CRISPR technology.
Scroll Up
Scroll Down
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv